These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
22. Cerebrospinal fluid synaptosomal-associated protein 25 is a key player in synaptic degeneration in mild cognitive impairment and Alzheimer's disease. Zhang H; Therriault J; Kang MS; Ng KP; Pascoal TA; Rosa-Neto P; Gauthier S; Alzheimers Res Ther; 2018 Aug; 10(1):80. PubMed ID: 30115118 [TBL] [Abstract][Full Text] [Related]
23. Elevated norepinephrine metabolism is linked to cortical thickness in the context of Alzheimer's disease pathology. van Hooren RWE; Verhey FRJ; Ramakers IHGB; Jansen WJ; Jacobs HIL Neurobiol Aging; 2021 Jun; 102():17-22. PubMed ID: 33667876 [TBL] [Abstract][Full Text] [Related]
24. Different regional patterns of cortical thinning in Alzheimer's disease and frontotemporal dementia. Du AT; Schuff N; Kramer JH; Rosen HJ; Gorno-Tempini ML; Rankin K; Miller BL; Weiner MW Brain; 2007 Apr; 130(Pt 4):1159-66. PubMed ID: 17353226 [TBL] [Abstract][Full Text] [Related]
26. Cognitive impairment in late-life bipolar disorder is not associated with Alzheimer's disease pathological signature in the cerebrospinal fluid. Forlenza OV; Aprahamian I; Radanovic M; Talib LL; Camargo MZ; Stella F; Machado-Vieira R; Gattaz WF Bipolar Disord; 2016 Feb; 18(1):63-70. PubMed ID: 26876913 [TBL] [Abstract][Full Text] [Related]
27. Accelerated inflammatory aging in Alzheimer's disease and its relation to amyloid, tau, and cognition. Cullen NC; Mälarstig AN; Stomrud E; Hansson O; Mattsson-Carlgren N Sci Rep; 2021 Jan; 11(1):1965. PubMed ID: 33479445 [TBL] [Abstract][Full Text] [Related]
28. Intra-individual correlations between quantitative THK-5351 PET and MRI-derived cortical volume in Alzheimer's disease differ according to disease severity and amyloid positivity. Park JE; Yun J; Kim SJ; Shim WH; Oh JS; Oh M; Roh JH; Seo SW; Oh SJ; Kim JS PLoS One; 2019; 14(12):e0226265. PubMed ID: 31834916 [TBL] [Abstract][Full Text] [Related]
29. Incremental value of biomarker combinations to predict progression of mild cognitive impairment to Alzheimer's dementia. Frölich L; Peters O; Lewczuk P; Gruber O; Teipel SJ; Gertz HJ; Jahn H; Jessen F; Kurz A; Luckhaus C; Hüll M; Pantel J; Reischies FM; Schröder J; Wagner M; Rienhoff O; Wolf S; Bauer C; Schuchhardt J; Heuser I; Rüther E; Henn F; Maier W; Wiltfang J; Kornhuber J Alzheimers Res Ther; 2017 Oct; 9(1):84. PubMed ID: 29017593 [TBL] [Abstract][Full Text] [Related]
30. Progressive medial temporal lobe atrophy during preclinical Alzheimer's disease. Pettigrew C; Soldan A; Sloane K; Cai Q; Wang J; Wang MC; Moghekar A; Miller MI; Albert M; Neuroimage Clin; 2017; 16():439-446. PubMed ID: 28879085 [TBL] [Abstract][Full Text] [Related]
31. Sex modifies APOE ε4 dose effect on brain tau deposition in cognitively impaired individuals. Yan S; Zheng C; Paranjpe MD; Li Y; Li W; Wang X; Benzinger TLS; Lu J; Zhou Y Brain; 2021 Nov; 144(10):3201-3211. PubMed ID: 33876815 [TBL] [Abstract][Full Text] [Related]
32. Longitudinal tau PET in ageing and Alzheimer's disease. Jack CR; Wiste HJ; Schwarz CG; Lowe VJ; Senjem ML; Vemuri P; Weigand SD; Therneau TM; Knopman DS; Gunter JL; Jones DT; Graff-Radford J; Kantarci K; Roberts RO; Mielke MM; Machulda MM; Petersen RC Brain; 2018 May; 141(5):1517-1528. PubMed ID: 29538647 [TBL] [Abstract][Full Text] [Related]
33. Tau Protein is Associated with Longitudinal Memory Decline in Cognitively Healthy Subjects with Normal Alzheimer's Disease Cerebrospinal Fluid Biomarker Levels. Tort-Merino A; Olives J; León M; Peñaloza C; Valech N; Santos-Santos MA; Càmara E; Grönholm-Nyman P; Martínez-Lage P; Fortea J; Molinuevo JL; Sánchez-Valle R; Laine M; Rodríguez-Fornells A; Rami L J Alzheimers Dis; 2019; 70(1):211-225. PubMed ID: 31177219 [TBL] [Abstract][Full Text] [Related]
34. The accumulation rate of tau aggregates is higher in females and younger amyloid-positive subjects. Smith R; Strandberg O; Mattsson-Carlgren N; Leuzy A; Palmqvist S; Pontecorvo MJ; Devous MD; Ossenkoppele R; Hansson O Brain; 2020 Dec; 143(12):3805-3815. PubMed ID: 33439987 [TBL] [Abstract][Full Text] [Related]
35. Discerning mild cognitive impairment and Alzheimer Disease from normal aging: morphologic characterization based on univariate and multivariate models. Liao W; Long X; Jiang C; Diao Y; Liu X; Zheng H; Zhang L; Acad Radiol; 2014 May; 21(5):597-604. PubMed ID: 24433704 [TBL] [Abstract][Full Text] [Related]
36. Atrophic Patterns of the Frontal-Subcortical Circuits in Patients with Mild Cognitive Impairment and Alzheimer's Disease. Zhao H; Li X; Wu W; Li Z; Qian L; Li S; Zhang B; Xu Y PLoS One; 2015; 10(6):e0130017. PubMed ID: 26066658 [TBL] [Abstract][Full Text] [Related]
37. Association Between Smoking and Cholinergic Basal Forebrain Volume in Healthy Aging and Prodromal and Dementia Stages of Alzheimer's Disease. Teipel S; Grothe MJ; J Alzheimers Dis; 2016 Apr; 52(4):1443-51. PubMed ID: 27079707 [TBL] [Abstract][Full Text] [Related]